Why Mineralys Therapeutics (MLYS) Is Getting Fresh Attention
Why Mineralys Therapeutics Stock Is In Focus After Earnings And Leadership Change
Mineralys Therapeutics (MLYS) is on investors’ radar after second quarter 2026 results showed a net loss of US$241.07 million, alongside the appointment of James J. Ferguson III, M.D., as Chief Medical Officer.
See our latest analysis for Mineralys Therapeutics.
Mineralys Therapeutics’ recent news arrives after a mixed run for investors, with the share price down 5.04% over 30 days and 14.07% over 90 days, yet a 1 year total shareholder return of 72.32% and 3 year total shareholder return of 97.31% pointing to earlier momentum that now appears to be fading as higher reported losses and the CMO transition reshape the perceived risk profile at a latest share price of US$25.65.
If you are weighing what else might be moving around key healthcare trends, this is a good moment to scan opportunities across 41 healthcare AI stocks.
Mineralys Therapeutics now trades at a sharp discount to both analyst targets and intrinsic estimates after its recent pullback. Given that wide gap, where does fair value really sit for this stock today?
Most Popular Narrative: 49.6% Undervalued
The most followed narrative for Mineralys Therapeutics pegs fair value at $50.88, which sits well above the latest close of $25.65. That gap is built on specific assumptions about lorundrostat, future earnings power, and how the market might price those earnings.
Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile, which could materially affect future revenue and earnings visibility.
Curious what has to happen for that fair value to stack up? The narrative leans heavily on ambitious revenue build, margin uplift and a rich future earnings multiple. The exact mix of growth, profitability, and share count is where the story really gets interesting.
Result: Fair Value of $50.88 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to factor in key risks for Mineralys Therapeutics, including regulatory outcomes for lorundrostat and the possibility of higher than expected cash burn.
Find out about the key risks to this Mineralys Therapeutics narrative.
Next Steps
With sentiment on Mineralys Therapeutics clearly mixed, this is a moment to move quickly and examine the full picture of risks and rewards yourself. To weigh both sides with the same data set, start with the 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Mineralys Therapeutics?
If Mineralys Therapeutics has your attention, do not stop there. Broaden your watchlist now using focused stock lists that surface clear, data driven opportunities.
- Target potential mispricings early by scanning the 48 high quality undervalued stocks that currently pass strict quality filters.
- Strengthen your downside protection by reviewing the 78 resilient stocks with low risk scores that pair resilient fundamentals with comparatively lower risk scores.
- Get ahead of the crowd by checking the screener containing 19 high quality undiscovered gems before the wider market starts paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com